Browse the evidence

A remotely delivered, 12-month GLP-1RA (semaglutide) supported weight management program achieves significant weight loss (mean 19.1% of starting weight) in participants who maintain an active subscription, but high withdrawal rates (60.4%) limit generalizability.

If you have obesity and are considering a GLP-1RA like semaglutide, a remote program can help you lose significant weight (around 19% on average) if you stick with it. However, be aware that many people drop out, often due to side effects or cost. To succeed, you need to be committed to the weekly injections and the digital support, and understand that stopping the medication likely leads to weight regain.

Tirzepatide produces significantly greater long-term total body weight loss and fat mass reduction compared to Semaglutide in real-world clinical practice, with effects becoming distinct after 6 months.

If you are choosing between Semaglutide and Tirzepatide for long-term weight management, Tirzepatide offers significantly greater weight loss after 12 months. To maximize results and protect your muscle, you must combine the medication with a program that includes strength training twice a week and a protein intake of 60-90 grams daily.

Females experience significantly greater weight loss than males when treated with incretin-based obesity medications (Semaglutide and Tirzepatide).

If you are male, expect that your weight loss may be slower than that of female peers taking the same medication. This is a known biological response. Do not be discouraged; the medication still provides significant metabolic benefits and fat loss, even if the scale moves slower.

Myostatin acts as a negative regulator of muscle hypertrophy and cardiac pathological hypertrophy, and its inhibition or reduction through exercise can promote muscle growth and protect against certain cardiac dysfunctions.

Consistent exercise naturally lowers myostatin, a protein that limits muscle growth. This is one reason why regular resistance training is effective for building muscle.

Bariatric surgery and incretin-based therapies (GLP-1 RAs, tirzepatide) reduce pancreatic disease burden and improve metabolic profiles relevant to pancreatic pathology.

If you are considering weight loss medications like GLP-1 agonists (e.g., semaglutide) or dual agonists (e.g., tirzepatide), current evidence suggests they do not increase the risk of pancreatitis or pancreatic cancer. They may actually help reduce pancreatic inflammation and disease burden by improving metabolic health.

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce modest weight loss (2.3–5%) in breast cancer patients, which is significantly attenuated compared to non-cancer populations, likely due to concurrent endocrine therapy.

If you have breast cancer and are taking hormone-blocking therapy, GLP-1 drugs like semaglutide will likely help you lose some weight, but not as much as they do for people without cancer. Expect a modest loss (around 2-5%) rather than dramatic results. This is likely because your cancer treatment changes your metabolism. It appears safe regarding cancer recurrence, but discuss timing with your oncologist.

GLP-1 receptor agonist use in breast cancer patients does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity.

For breast cancer patients, GLP-1 drugs appear safe regarding cancer recurrence. They may also offer significant cardiovascular protection, which is valuable since some cancer treatments can stress the heart. This benefit exists independently of weight loss.

Sympathomimetic agents (phentermine, phentermine/topiramate, naltrexone/bupropion) cause mild gastrointestinal side effects (constipation, dry mouth, nausea) with lower discontinuation rates compared to GLP-1 agonists.

If you take a sympathomimetic medication like phentermine or naltrexone/bupropion, you may experience mild side effects like constipation or dry mouth. These are generally less severe than the GI side effects associated with GLP-1 agonists. Stay hydrated and monitor your symptoms.

The cardiometabolic benefits of exercise, particularly on glucose regulation and inflammation, may be attenuated or dependent on weight loss in individuals with obesity.

Be aware that while exercise is beneficial, achieving weight loss may be necessary to fully improve glucose regulation and inflammation in obesity. However, do not stop exercising if weight loss is difficult; other benefits remain.

Women with type 2 diabetes treated with GLP-1 receptor agonists achieve significantly greater weight loss than men after 12 months, despite similar glycemic control improvements.

If you are a woman with Type 2 Diabetes on a GLP-1 agonist, you are statistically more likely to achieve significant weight loss (over 5% or 10%) than a man on the same medication class, particularly after 6-12 months. This does not mean men won't lose weight, but the magnitude of benefit tends to be greater in women. Glycemic control (HbA1c) improves similarly for both sexes.

Glucagon receptor (GCGR) agonism increases energy expenditure and promotes weight loss, particularly when combined with GLP-1R and/or GIPR agonism in dual or triple receptor agonists.

Current obesity treatments often lead to weight regain because they don't significantly increase energy expenditure. New drugs that activate the glucagon receptor (GCGR), either alone or combined with GLP-1/GIP drugs, are designed to boost energy expenditure and prevent this metabolic slowdown. While early results show significant weight loss (up to 24% in some trials), long-term clinical data is still emerging, and these are prescription medications requiring medical supervision.

In a mixed population of diabetic and non-diabetic patients, liraglutide (up to 3 mg) and semaglutide (up to 1 mg) produce statistically equivalent weight loss, contradicting findings from trials using higher doses or specific diabetic cohorts.

If you are using liraglutide or semaglutide at lower, standard starting-to-maintenance doses (up to 3mg and 1mg respectively), expect similar weight loss results. The perceived superiority of semaglutide in marketing often relies on higher doses (2.4mg) not used in this study. Focus on adherence and titration rather than switching solely for weight loss efficacy at these doses.

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

Tirzepatide is a broadly acceptable and preferred long-term treatment for comorbid obesity and obstructive sleep apnea (COBOSA) by patients, offering efficacy comparable to CPAP with different adherence profiles.

If you have obesity and sleep apnea, tirzepatide is a valid, once-weekly treatment option that many patients prefer over CPAP. Discuss with your doctor if it's right for you, considering factors like cost, side effects, and your preference for injections vs. devices.

Reallocating 30 minutes of daily sedentary time to moderate-to-vigorous physical activity (MVPA) in young, healthy, active adults increases daily energy intake by approximately 113–120 kcal and alters appetite hormones (higher fasting ghrelin, lower postprandial PYY) to compensate for energy expenditure, without affecting hedonic food reward traits.

If you are already active and healthy, increasing your moderate-to-vigorous exercise by 30 minutes a day will likely make you hungrier and cause you to eat about 120 more calories. This is your body's natural way of balancing energy. To manage weight, you must consciously account for this increased intake rather than assuming exercise alone creates a deficit. If your goal is performance, use this hunger to fuel your activity.

GLP-1 receptor agonist use during radiation therapy causes rapid weight loss and anatomic changes that compromise immobilization reproducibility and dosimetric accuracy, necessitating adaptive radiotherapy or temporary holding of the medication.

If you are taking GLP-1 drugs (like Ozempic or Wegovy) while getting radiation, tell your radiation team immediately. These drugs cause weight loss and stomach changes that can make your radiation treatment less accurate. Your team may ask you to pause the drug or scan you more often to adjust the treatment plan. This is to keep you safe and ensure the radiation hits the tumor correctly.

Dose de-escalation (tapering) or low-dose maintenance therapy may modestly limit the rate and magnitude of weight regain compared to abrupt cessation, but robust randomized evidence is currently lacking.

If you want to stop your incretin medication, talk to your doctor about tapering the dose or extending the time between injections rather than stopping abruptly. While this might help slow down weight regain, it is not a guaranteed solution, and you should expect some regain. Continuing at a lower dose is generally better than stopping completely.

Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 and dual/tri-agonists, produce significant weight loss and cardiometabolic improvements in real-world settings, though response heterogeneity, high discontinuation rates, and post-cessation weight regain remain unresolved challenges.

NuSH therapies (like semaglutide or tirzepatide) are highly effective for significant weight loss and metabolic health in real-world use, but they are not magic bullets. Expect a significant portion of people to not respond well, experience side effects leading to stopping the drug, or regain weight after stopping. Success requires individualized dosing, lifestyle support, and an understanding that obesity management is often a long-term commitment rather than a quick fix.

β-hydroxy-β-methylbutyrate (HMB, 3 g/day) has conditional utility for muscle hypertrophy, showing benefits primarily during high training stress or caloric deficits, but is largely neutral in well-fed, resistance-trained individuals.

If you are dieting or doing extremely high-volume training, 3g of HMB daily might help preserve muscle. If you are eating well and training normally, HMB is likely a waste of money as it shows no benefit in this group.